None EN

Shandong Simcere Medgenn Bio-Pharmaceutical discloses new KRAS G12D inhibitors

[] BioWorld 2026-08-11 10:07:09

CancerShandong Simcere Medgenn Bio-Pharmaceutical discloses new KRAS G12D inhibitorsShandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd. has reported GTPase KRAS (G12D mutant) inhibitors found to be useful for the treatment of non-small-cell lung and pancreatic cancer.

simcere medgenn pharmaceutical kras g12d inhibitors discloses cancer nshandong

Read Full Article Back to Feed More None